Description
Product Description:
Lenvatinib, the first new first-line treatment for HCC approved in Japan, is a multikinase inhibitor that disrupts the VEGFR1, VEGFR2, and VEGFR3 signaling pathways. It is used to treat differentiated thyroid cancer (DTC), renal cell carcinoma, and hepatocellular carcinoma (HCC).
Features:
Product name: Lenvanix
Generic name: Lenvatinib
Dosage form: capsule
Available pack sizes: 30 cans
Available strengths: 4 mg
Registerable
Reviews
There are no reviews yet.